The benefits, costs and feasibility of a low incidence COVID-19 strategy. (2022)
Attributed to:
Biomedicine and Beyond: The Social and Regulatory Dimensions of Therapeutics in Japan and the UK
funded by
FIC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.81311
Publication URI: https://www.repository.cam.ac.uk/handle/1810/333895
Type: Journal Article/Review